- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06418126
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer (TNBC-RT2023)
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer : TNBC-RT2023
Recurrence of triple-negative breast cancer (TNBC) occurs in around 30% of patients within 3 years of treatment. For some TNBC patients, recurrence occurs on average 2.6 years after treatment, while for others recurrence does not occur early. TNBC patients can therefore be divided into two groups: those with early recurrence and those who respond well to treatment.
At present, there are no biomarkers to differentiate these two groups. Some studies suggest that radiation-induced inflammatory cytokines may stimulate the development of new metastases. Gene expression profiling or protein signatures have not been able to define such biomarkers.
The aim of this research protocol is to recruit patients to evaluate if the elevation of the cytokines IL-1β, IL-5 and IL-6 in plasma collected during radiotherapy can be used to predict TNBC patients at high risk of recurrence.
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: blood sampling before radiotherapy
- Biological: blood sampling after the fourth radiotherapy session
- Other: collection of acute toxicity (radiodermatitis)
- Other: collection of late toxicity
- Other: collection of disease status
- Radiation: Radiotherapy - Breast +/- lymph node areas
- Radiation: Radiotherapy - Boost operating bed
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Valérie SARTORI
- Phone Number: 33 0368767223
- Email: v.sartori@icans.eu
Study Contact Backup
- Name: Manon VOEGELIN
- Phone Number: 33 0368767360
- Email: promotion-rc@icans.eu
Study Locations
-
-
-
Strasbourg, France, 67033
- Recruiting
- Institut de cancérologie Strasbourg Europe
-
Contact:
- Valérie SARTORI
- Phone Number: 33 0368767223
- Email: v.sartori@icans.eu
-
Contact:
- Manon VOEGELIN
- Phone Number: 33 0368767360
- Email: promotion-rc@icans.eu
-
Principal Investigator:
- Georges NOEL
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Women with TNBC breast cancer who meet the following criteria:
- Women aged 18 and over;
- Any tumor size (pT stage);
- Regional lymph node pN0 to pN3;
- Patient with pathologically confirmed TNBC (estrogen and progesterone receptor negative and HER2 negative);
- Neo- or adjuvant chemotherapy followed by radiotherapy;
- No evidence of distant metastasis at time of diagnosis;
- Primary tumor removed by conservative surgery with negative margins;
- Patient covered by the French social security system (for French patients).
Exclusion Criteria:
- Distant metastasis at the time of diagnosis;
- Pregnant or breast-feeding women;
- Woman deprived of liberty, under guardianship or trusteeship.
- Patient unable to give consent
- Patient unable to speak French
- Patients unable to undergo regular long-term surveillance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Women with TNBC breast cancer
Patients will be recruited before the start of radiotherapy. A blood sample (20 ml) will be taken before radiotherapy and immediately after the 4th radiotherapy session. They will be followed up annually for 5 years after the end of treatment, to determine whether their cancer has recurred. |
A blood sample (20 ml) will be taken prior to radiotherapy
A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
for the entire duration of radiotherapy
every year for 5 years
throughout the study
40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive value of recurrence associated with the appearance of inflammatory cytokines
Time Frame: up to 5 years
|
Determine whether TNBC patients who respond poorly to radiotherapy can be identified by the appearance of inflammatory cytokines in the blood during radiotherapy.
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine whether the increased invasive capacity of TNBC cells incubated with plasma collected during radiotherapy will be associated with recurrence.
Time Frame: up to 5 years
|
TNBC cells will be incubated with plasma collected before or during radiotherapy.
Boyden chambers will be used to determine the increase in cell invasion.
|
up to 5 years
|
To determine whether the development of metastases in a mouse model injected with TNBC D2A1 cells pre-incubated with plasma collected during radiotherapy will be associated with recurrence.
Time Frame: up to 5 years
|
Number and sizes of metastases to the lungs will be determined after i.v.
plasma injection in Balb/c mice.
|
up to 5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple-negative Breast Cancer
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on blood sampling before radiotherapy
-
Centre Oscar LambretInstitut de Biologie de LilleTerminatedMelanoma | Kidney Neoplasms | Carcinoma, Hepatocellular | Colorectal NeoplasmsFrance
-
University Hospital, GhentUniversity Ghent; Vlaams Instituut voor BiotechnologieCompleted
-
Royal Marsden NHS Foundation TrustImperial College Healthcare NHS TrustCompleted
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
National Taiwan University HospitalUnknown
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance